following a full submission
thiotepa (Tepadina) is not recommended for use within NHS Scotland.
Indication under review: In combination with other chemotherapy medicinal products:
1) with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;
2) when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Two uncontrolled, non-randomised studies including patients with advanced non-Hodgkin’s lymphoma or Hodgkin’s disease have reported data for non-relapse mortality and overall survival.
The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.
Download detailed advice127KB (PDF)
Medicine details
- Medicine name:
- thiotepa (Tepadina)
- SMC ID:
- 790/12
- Indication:
- In combination with other chemotherapy medicinal products (1): with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; (2): when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Pharmaceutical company
- Adienne
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 July 2012